SINGAPORE-based health-tech firm Biofourmis has developed a tool that uses artificial intelligence to monitor a patient's condition and can predict whether a person's health is deteriorating or improving, as well as a drug or therapy's effectiveness.
The health-tech firm plans to offer RhythmAnalytics as a Software-as-a-Service to cardiac monitoring organisations to improve accuracy and scalability of their ECG analysis, in turn improving throughput and efficiencies in cardiac monitoring centres. In November 2018, Biofourmis announced a partnership with Brigham and Women's Hospital, offering RhythmAnalytics as an investigational device exemption. Currently, the software is being used to continuously monitor for cardiac arrhythmia and manage patients at home, through the Brigham's Hospital Program.
Kuldeep Singh Rajput, founder and CEO of Biofourmis said: “Comprehensive diagnosis of a patient’s cardiac health requires longer continuous monitoring and full characterisation of multiple arrhythmias. We are on a mission of predicting and preventing serious medical events using software-based therapeutic intervention and RhythmAnalytics is an integral part of our Digital Therapeutics platform that would enable prescription of the right dose, to the right patient at the right time.
Biofourmis was founded in Singapore in November 2015 and now has over 40 employees in Singapore and Boston. Mr Rajput was recently listed on Forbes 30 under 30 list in Asia.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »